Senexin B

ID: ALA4076837

Chembl Id: CHEMBL4076837

Cas Number: 1449228-40-3

PubChem CID: 71661259

Max Phase: Phase

Molecular Formula: C27H26N6O

Molecular Weight: 450.55

Molecule Type: Small molecule

Names and Identifiers

Synonyms: Bcd-115 | Senexin b | BCD-115 | Senexin B|1449228-40-3|SenexinB|Senexin-B|BCD-115|E2X758P2BZ|CHEMBL4076837|4-[2-[6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl]ethylamino]quinazoline-6-carbonitrile|4-((2-(6-((4-Methyl-1-piperazinyl)carbonyl)-2-naphthalenyl)ethyl)amino)-6-quinazolinecarbonitrile|4-((2-(6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl)ethyl)amino)quinazoline-6-carbonitrile|6-Quinazolinecarbonitrile, 4-((2-(6-((4-methyl-1-piperazinyl)carbonyl)-2-naphthalenyl)ethyl)amino)-|UNII-E2Show More⌵

Canonical SMILES:  CN1CCN(C(=O)c2ccc3cc(CCNc4ncnc5ccc(C#N)cc45)ccc3c2)CC1

Standard InChI:  InChI=1S/C27H26N6O/c1-32-10-12-33(13-11-32)27(34)23-6-5-21-14-19(2-4-22(21)16-23)8-9-29-26-24-15-20(17-28)3-7-25(24)30-18-31-26/h2-7,14-16,18H,8-13H2,1H3,(H,29,30,31)

Standard InChI Key:  VNADJTWHOAMTLY-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA4076837

   SENEXIN B

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 450.55

Molecular Weight (Monoisotopic): 450.2168

AlogP: 3.70

#Rotatable Bonds: 5

Polar Surface Area: 85.15

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.85

CX LogP: 3.50

CX LogD: 3.39

Aromatic Rings: 4

Heavy Atoms: 34

QED Weighted: 0.50

Np Likeness Score: -1.36

References

1. Ono K, Banno H, Okaniwa M, Hirayama T, Iwamura N, Hikichi Y, Murai S, Hasegawa M, Hasegawa Y, Yonemori K, Hata A, Aoyama K, Cary DR..  (2017)  Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives.,  25  (8): [PMID:28302507] [10.1016/j.bmc.2017.02.038]

2. Philip S, Kumarasiri M, Teo T, Yu M, Wang S..  (2018)  Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?,  61  (12): [PMID:29266937] [10.1021/acs.jmedchem.7b00901]

3. Unpublished dataset, 

4.  (2019)  Compounds for treatment of hypoproliferative disorders, 

5.  (2020)  Quinoline-based compounds and methods of inhibiting cdk8/19, 

6.  (2020)  3-amino-4-(4-(4 (dimethylcarbamoyl) phenyl)-1,4-diazepan-1-yl) thieno [2,3-b] pyridine-2-carboxamide for use in cancer therapy and formulations comprising the same, 

7.  (2019)  Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventive methods for cancer, 

8. Zhang L, Cheng C, Li J, Wang L, Chumanevich AA, Porter DC, Mindich A, Gorbunova S, Roninson IB, Chen M, McInnes C..  (2022)  A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.,  65  (4.0): [PMID:35114084] [10.1021/acs.jmedchem.1c01951]

9. Wu D, Zhang Z, Chen X, Yan Y, Liu X..  (2021)  Angel or Devil ? - CDK8 as the new drug target.,  213  [PMID:33257171] [10.1016/j.ejmech.2020.113043]

Source

Source(3):

• Scientific Literature
• Clinical Candidates
• Patent Bioactivity Data